Pharmaceutical Executive: September 2023

September 12, 2023

Click the title above for a link to open the Pharmaceutical Executive September 2023 issue in an interactive PDF format.

September 11, 2023

Lisa LeCointe-Cephas, SVP, chief ethics and compliance officer and office of general counsel, human health, Merck, uses her unique style of leadership—stop, drop, and roll—while elevating voices that need to be heard.

September 11, 2023

Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.

September 11, 2023

Early success ignites promise in reshaping standards of care for HER2 breast cancer.

September 11, 2023

Bacteria killer signals a milestone—and momentum—for microbiome therapeutics.

September 11, 2023

Injection buys valuable time to formulate care game plans in diabetes management.

September 11, 2023

Ushering in a novel class of drugs that attacks HIV at multiple stages of replication.

September 10, 2023

First-of-its-kind treatment offers hope in the fight against rare heart disease.

September 08, 2023

Integrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.

September 08, 2023

With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.

September 07, 2023

Strong economic data in other sectors mean rising ‘real’ rates.

September 06, 2023

The implications of Twitter’s rebrand for healthcare marketing.

September 06, 2023

Embrace the tools that solve real problems and make life easier.

September 06, 2023

Disruptive strategies are essential to grow the pharma industry.

September 03, 2023

September 03, 2023

One of the most special things about Pharmaceutical Executive®, in my opinion, is when people share their stories—where they came from; how their upbringing or education or background impacted their desire to work in pharma; any personal ties to their work, such as finding new treatments in a specific disease state due to a loved one having been impacted by that same disease; and just generally sharing their passion for their work. As someone who’s worked in pharma journalism for many years, there’s something extraordinary to hear about the why for individuals.